Avita Therapeutics – Consensus Indicates Potential 157.5% Upside

Broker Ratings

Avita Therapeutics found using ticker (RCEL) now have 5 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 60 and 35 calculating the average target price we see 45.2. Now with the previous closing price of 17.55 this would imply there is a potential upside of 157.5%. The day 50 moving average is 21.07 and the 200 moving average now moves to 24.52. The market cap for the company is $380m. Find out more information at: http://www.avitamedical.com

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient’s own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp